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Abstract
Chronic orofacial pain is a significant health problem requiring identification of regulating processes. Involvement of epigenetic
modifications that is reported for hindlimb neuropathic pain experimental models, however, is less well studied in cranial nerve
pain models. Three independent observations reported here are the (1) epigenetic profile in mouse trigeminal ganglia (TG)
after trigeminal inflammatory compression (TIC) nerve injury mouse model determined by gene expression microarray, (2)
H3K9 acetylation pattern in TG by immunohistochemistry, and (3) efficacy of histone deacetylase (HDAC) inhibitors to
attenuate development of hypersensitivity. After TIC injury, ipsilateral whisker pad mechanical sensitization develops by day
3 and persists well beyond day 21 in contrast to sham surgery. Global acetylation of H3K9 decreases at day 21 in ipsilateral TG .
Thirty-four genes are significantly (p < 0.05) overexpressed in the ipsilateral TG by at least two-fold at either 3 or 21 days posttrigeminal inflammatory compression injury. The three genes most overexpressed three days post-trigeminal inflammatory
compression nerve injury are nerve regeneration-associated gene ATF3, up 6.8-fold, and two of its regeneration-associated
gene effector genes, Sprr1a and Gal, up 174- and 25-fold, respectively. Although transcription levels of 25 of 32 genes
significantly overexpressed three days post-trigeminal inflammatory compression return to constitutive levels by day 21,
these three regeneration-associated genes remain significantly overexpressed at the later time point. On day 21, when tissues
are healed, other differentially expressed genes include 39 of the top 50 upregulated and downregulated genes. Remarkably,
preemptive manipulation of gene expression with two HDAC inhibitors (HDACi’s), suberanilohydroxamic acid (SAHA) and
MS-275, reduces the magnitude and duration of whisker pad mechanical hypersensitivity and prevents the development of a
persistent pain state. These findings suggest that trigeminal nerve injury leads to epigenetic modifications favoring overexpression of genes involved in nerve regeneration and that maintaining transcriptional homeostasis with epigenetic modifying drugs
could help prevent the development of persistent pain.
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Introduction
Histone deacetylase inhibitors (HDACi) show promise
as treatment for neuropathic pain. The efficacy of epigenetic modifying drugs for treatment of models of hindlimb neuropathic pain has been well established,1 but
studies currently involving the role of epigenetics in orofacial pain and thus the efficacy of epigenetic modifying
drugs associated with orofacial pain has lagged behind
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this rapidly advancing field. There are four classes of
HDACs: zinc-dependent HDACs I (HDAC 1–3 and
8); IIa (HDAC 4, 5, 7 and 9); IIb (HDAC 6 and 10);
and IV (HDAC 11); and biochemically unique class III,
a family of NADþ-dependent proteins known as sirtuins
(SIRT 1–7) involved particularly in mitochondrial biogenesis. The highest expression of HDAC 1 (class I) has
been shown in injured dorsal root ganglia (DRG) following spinal nerve ligation.2 Evidence that epigenetic
changes are involved in the development of neuropathic
pain has been shown since class I HDACi’s (HDACi)
treatments with suberanilohydroxamic acid (SAHA) and
MS-275 produce analgesia in sciatic nerve injury
models.3–5 Both experimental and clinical studies have
demonstrated class II HDACi’s (trichostatin A, givinostat (ITF 2357)) have therapeutic potential for inflammatory conditions.6–8 Four HDACi’s are already Food
and Drug Administration (FDA) approved for treatment of some forms of cancer.9 A potential benefit of
HDACi’s for neurodegenerative diseases, such as
Alzheimer’s and Huntington’s, has also been
described.10,11 These drugs work by modifying DNA
or DNA-associated proteins such as histones such that
gene expression can be manipulated, possibly restoring
homeostatic expression levels. Whether HDACi’s produce analgesia or influence the transition from acute to
persistent pain in models of orofacial neuropathic pain is
not yet well studied. Thus, we examined the epigenetic
changes in TG due to trigeminal nerve injury as a first
step and determined whether HDACi’s would reduce the
pain-related behaviors induced by the trigeminal inflammatory compression (TIC) nerve injury model in mice.
Two class I HDACi’s, SAHA and MS-275, were
tested in this study.12 SAHA, also named Vorinostat,
(the trade name is Zolinza), is a class I and II HDACi
that was the first HDACi approved by the U.S. FDA for
the treatment of cutaneous T-cell lymphoma.13 MS-275,
Entinostat, also known as SNDX-275, is a benzamide
class I inhibitor of HDAC 1 (IC50 ¼ 300 nM) and
HDAC 3 (IC50 ¼ 8 mM) that is undergoing clinical
trials for the treatment of various cancers.

Materials and methods
Animals
Three experiments were performed with male BALB/C
mice with and without TIC nerve injury following
behavioral testing:
1. Microarray (four groups of n ¼ 6 each, total of 24
mice, only three ipsilateral TGs per group were used
for each microarray). The four groups were: 3-day
naı̈ve, 3-day TIC, 21-day naı̈ve, and 21-day TIC;

Molecular Pain
2. Immunohistochemistry (four groups of n ¼ 3 each,
total of 12 mice). The four groups were: 3-day
naı̈ve, 3-day TIC, 21-day naı̈ve, and 21-day TIC.
Measurement of ipsilateral TG neuron diameters (n ¼ 3);
3. HDACi’s treatment (three groups of n ¼ 5 each, total
of 15 mice). The three groups were: TIC þ Vehicle,
TIC þ SAHA, TIC þ MS275.
Mice received from Envigo-Harlan (Indianapolis, IN)
weighed between 20 and 22 g during the week of acclimitization. BALB/c mice with hypersensitivity are consistently easier to handle in repeated pain-related
behavioral testing paradigms extending over numerous
weeks. Mice were kept in ventilated animal housing with
constant temperature (23  2 C) on a reversed 10/14
h dark/light cycle. Food and water were provided ad
libitum. Experiments were carried out in accordance
with the guidelines established by National Institute of
Health (NIH) and the International Association for the
Study of Pain regarding the care and use of animals for
all experimental procedures. Protocols were approved by
the Institutional Animal Care and Use Committee at the
University of Kentucky.

Induction of TIC nerve injury
All surgeries were completed in a sterile environment
under a surgical microscope in mice anesthetized with
isoflurane (2–5%) as validated previously.14,15 The top
of the head was shaved and the mice secured in a stereotactic frame. In order to prevent the eyes from drying
out during the operation, Artificial Tears Ointment
(Rugby Laboratories, Inc. Duluth, GA) was applied to
both eyes. A 15-mm skin incision was made in an anterior to posterior direction at the midline of the head. The
conjunctiva of the orbit was opened along the top inner
corner of the left eye bony orbit (eye socket) with the tip
of a surgical scalpel. Cotton balls were used to minimize
bleeding within the orbital cavity and as tools for blunt
isolation of the infraorbital nerve lying in the infraorbital bony fissure. The infraorbital nerve was freed from
the bone in the orbital cavity in order to insert a 2 mm
length of 6–0 chromic gut suture between the infraorbital
nerve and the maxillary bone, positioned as close to the
anterior maxillary nerve branch as possible. Skin incisions were closed with 5–0 nylon non-absorbable monofilament suture. Mice were given a three-day recovery
period prior to further behavioral testing.

Exon microarray and gene expression
profiling analysis
Gene expression profiling was performed on TGs from
mice with/without TIC nerve injury during the acute
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phase (3 days) and persistent (21 days) post-injury time
points for comparisons to their corresponding naı̈ve control groups (n ¼ 24). The TGs were freshly dissected,
transferred to RNAlaterVR , a RNA stabilization solution
(Life Technologies, Grand Island, NY), and stored at
80 C. Total RNA from ipsilateral TGs was isolated
using the RNeasy Mini Kit (Qiagen, Valencia, CA).
Each replicate was derived from a single ipsilateral TG
from n ¼ 3 mice per group/per time point and run in
duplicate. RNA expression levels were determined with
the Mouse Gene 2.0 Array (Affymetrix, Santa Clara,
CA, USA) at MicroArray Core Facility under the direction of Dr Kuey-Chu Chen in the University of
Kentucky. The Mouse Gene 2.0 Array contained
41,345 transcript cluster sets.
The gene ontology (GO) for each transcript was
obtained using the NIH gene database (https://www.
ncbi.nlm.nih.gov/gene). We used the GO annotation
analysis corresponding to the Mus musculus (house
mouse) description since this most closely correlates to
the BALB/C mice used in the research protocol. Process,
function, and pathway enrichment analysis was performed using The Database for Annotation,
Visualization and Integrated Discovery (DAVID) v6.
8 (National Institute of Allergy and Infectious
(NIAID)/NIH).16,17 The Kyoto Encyclopedia of Genes
and Genomes (KEGG) was used in differentiating genes
in the pathway analysis. Biological processes, molecular
functions, and pathways influenced by TIC injury were
identified. Gene expression profiling with Affymetrix
Gene Chip Analysis Suite 5.0 software was performed.
Data were analyzed at the transcript cluster level; statistical analysis of the transcript cluster-level data was
done via paired t-tests. Correction for multiple testing
was done using a stepwise procedure at a false discovery
rate of 5%.18–20

Quantitative real-time PCR (qPCR)
RNA was reverse transcribed and quantified by quantitative real-time PCR.21 Sprr1a, Gal, Atf3, and GAPDH
TaqMan gene expression assays were purchased from
Life Technologies Corporation (Carlsbad, CA). Realtime PCR was performed on an ABI Prism 7700
Sequence Detection system (PE Applied Biosystems,
Foster City, CA, USA) in a 20 ml reaction volume consisting of final concentrations of 1X TaqMan Universal
PCR master mix (PE Applied Biosystems) and 1
respective gene expression assays using default conditions. Relative mRNA levels were calculated by 2–(CT
test  CT GAPDH)
 100% using GAPDH as the reference
gene.22
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Immunofluorescent staining
The TGs were dissected from 4% paraformaldehyde perfused mice, cryoprotected in 30% sucrose prior to freezing, and cryosectioned (10 mm). Serial sets were collected
for immunostaining with 100 mm between sections to
allow non-overlapping cell counts. Each serial set with
five to seven sections was mounted onto SuperfrostVR
Plus microscope slides (VWR, Radnor, PA) and stored
at 80 C. On the day of immunostaining, the sections
were blocked in 3% normal goat serum (NGS) and then
incubated overnight at room temperature with the primary antibody mixture in 3% NGS: rabbit polyclonal
anti-acetyl histone H3K9 antibody (1:300, Epigentek
Group) and mouse monoclonal anti-neuronal nuclei/
plasma (NeuN) (1:300, Millipore Corporation). To
study the H3K9 expression in non-neuronal cells, dual
staining was done to localize immunoreactivity for glutamine synthetase (Gl Syn, E-4 antibody, 1:300; Santa
Cruz Biotechnology, INC) to identify the satellite glial
cells. Sections were washed the next day with 0.1 M PBS
(pH 7.4) and incubated with secondary antibodies for 1
hour: goat anti-mouse IgG Alexa Fluor 594 and goat
anti-rabbit IgG Alexa Fluor 488 (1:1000; Invitrogen,
Grand Island, NY). After 3  5 min 0.1 M PBS (pH
7.4) washes, the slides were coverslipped with anti-fade
mounting media (Vector Laboratories, Burlingame,
CA). Images of TG sections were collected with
MetaVue Program (Molecular Devices, Sunnyvale,
CA) using a Nikon E100 microscope (Nikon
Instruments, Inc., Melville, NY).

Image analysis
Multiple images were captured from 5 to 7 tissue sections with 100 mm interspacing to span the entire trigeminal ganglia (TG) of each animal for analysis with the
Metamorph off-line program. Images from each of the
TG sections were stitched together with computer assistance allowing identification of V1, V2, or V3 TGs. TG
neurons were measured with the Metamorph off-line
program and classified by their diameters. Anti-NeuN
antibody staining was used to visualize the TG neurons
and allowed counting of 3,000–6,000 neurons for the V2
TG by investigators blinded to experimental group designation for comparisons among experimental groups.
The number of neurons labeled with H3K9ac was
counted to determine the percentage of total neurons
double labeled with NeuN and H3K9ac for comparisons
between animals with/without TIC injury.

Detection of whisker pad mechanical hypersensitivity
Behavioral threshold measurements on the whisker pads
were taken pre-surgery as baseline and at post-surgery
days 3, 7, 14, 21, and 28. The mice were acclimated to the
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testing room 30 min prior to testing. Mice were previously habituated to investigators and the von Frey filaments several times prior to data collection. Mechanical
thresholds of the whisker pad-infraorbital nerve receptive field were determined using the modified up-down
method23 as we described previously for the TIC
model.14,15 Eight graded von Frey fiber filaments
(0.008 g (1.65); 0.02 g (2.36); 0.07 g (2.83); 0.16 g
(3.22); 0.4 g (3.61); 1.0 g (4.08); 2.0 g (4.31); 6.0 g
(4.74); Stoelting, Wood Dale, IL) were used to determine
mechanical sensitivity beginning with the 3.22 filament.
During testing, mice were gently restrained in soft cotton
gloves with their head exposed for application of von
Frey filament to the whisker pads on both sides. Each
filament was applied up to five times to obtain three
positive or negative responses with at least 5 s intervals
between stimulations. Head withdrawal from the filament or a paw swipe was considered a positive response.
Data were analyzed with a curve-fitting algorithm that
allowed for calculation of the 50% mechanical withdrawal threshold (in gram force). A decreased mechanical threshold is an index of mechanical hypersensitivity
or allodynia.
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Results
Mechanical hypersensitivity develops on the ipsilateral
whisker pad after TIC injury
Mechanical hypersensitivity developed on the ipsilateral
whisker pads by day 3 post-TIC injury in contrast to
naı̈ve controls or the contralateral whisker pads
(Figure 1). Six mice were euthanized for gene expression
profiling for each group on days 3 and 21. Compared to
the average ipsilateral baseline mechanical threshold of
all mice (3.02  0.36 g), mechanical threshold decreased
on the ipsilateral whisker pad to an average of 0.02
 0.006 g by day 3 after TIC injury. The mechanical
threshold remained at a low level through day 21 (0.11
 0.06 g), indicating success in producing stable mechanical hypersensitivity on the side ipsilateral to the nerve
injury (Figure 1(a)). Compared with their own baseline
and with the naı̈ve control group, mechanical hypersensitivity of the ipsilateral whisker pad of TIC-injured mice
was statistically significant at all the time points tested.

Drug treatment
The pan-HDAC inhibitor SAHA (50 mg/kg) and
HDAC1-selective inhibitor MS-275 (3 mg/kg) (Cayman
Chemical Company, Ann Arbor, MI) were dissolved in
30% dimethyl sulfoxide (DMSO) in normal saline and
administered over a prolonged 12-day drug treatment
scheme spanning the day of surgery.5 Drugs and vehicle
controls (30% DMSO in saline) were given subcutaneously (s.c.) for five consecutive days prior to and continued for seven consecutive days following TIC injury.
Behavioral testing was done every other day during
drug
treatments
for
comparisons
to
pretreatment baselines.

Statistical analysis
Whisker pad mechanical thresholds were averaged for
naı̈ve or TIC-injured mice receiving SAHA, MS-275,
or vehicle. The behavioral data were expressed as
mean  SE using two-way analysis of variance
(ANOVA) with post-hoc testing with Tukey’s multiple
comparisons over time. The percentages of H3K9acpositive neurons were averaged for naı̈ve and TIC
injury animals and compared using Student’s t-tests. A
p value of  0.05 was considered significant. Statistical
analysis of the transcript cluster-level data comparisons
was done via paired t-tests.

Figure 1. Trigeminal nerve injury (TIC) causes persistent
mechanical hypersensitivity of the ipsilateral whisker pad. The
average 50% mechanical threshold value (grams force) was determined with von Frey fiber stimulation of the ipsilateral (a) and
contralateral (b) whisker pads of mice with/without TIC injury
(n ¼ 6 per group). The averaged thresholds for naı̈ve (䉬) and TIC
nerve injury (䊏) mice are shown. The ipsilateral and contralateral
averages of mechanical threshold values for naı̈ve mice are similar
as expected. The contralateral mechanical threshold values of TIC
injury mice were similar to naı̈ve controls and did not change from
their baseline over time. ***p < 0.001, two-way ANOVA, Tukey’s
multiple comparisons test, n ¼ 6 per group.
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The averaged mechanical threshold for the contralateral
whisker pad (2.74  0.45 g) after TIC injury was similar
to the naive controls (2.378  0.49 g) (Figure 1(b)).

Genes differentially expressed in TG following
TIC injury
Transcriptional expression changes caused by TIC injury
at the genome-wide level were analyzed by gene expression
profiling of ipsilateral TGs at day 3 and 21 post-injury.
Total RNA was isolated and processed for Mouse Gene
2.0 Array analysis. We identified 27,985 transcript cluster
sets associated with gene assignments according to the
supplier and/or DAVID (Database for Annotation,
Visualization and Integrated Discovery NIAID/NIH, see
https://david.ncifcrf.gov).15,16 Of these, signal intensities of
367 were increased >50% and two were decreased >50%
in mice on day 3 post-TIC injury compared to n€aives. On
day 21 post-TIC injury, 56 were increased >50% and 66
were decreased >50% (data available upon request).
Top 50 differentially expressed genes. The 50 genes most upand downregulated by at least 50% are presented in
Tables 1 and 2, for the days examined. Of note, the
small proline-rich repeat protein 1A (Sprr1a), an axon
regeneration-associated
gene
(RAG),
was
induced > 174-fold three days after TIC injury and
remained upregulated > 15-fold three weeks after TIC
injury. In addition, two other RAGs, Gal and Atf3,
were highly upregulated 25- and 7.8-fold on day 3,
respectively, and remained upregulated 2.4- and 2.7fold three weeks post-TIC injury.
Differentially expressed genes after TIC injury unique to days 3
and 21. Most striking was the large number of genes on
day 21 of the 50 most up- and downregulated that were
not expressed on day 3. The differentially expressed genes
at day 21 not in common with day 3 are presented in
BOLD font in Table 2. This included 39 upregulated
genes and 34 downregulated genes at 21 days. Genes
uniquely expressed on day 3, shown highlighted in
BOLD font in Table 1, included 24 upregulated genes
and 1 downregulated gene. It is important to note that
due to the experimental design of this study, it is not
possible to distinguish tissue injury-mediated gene expression changes at day 3 from expression mediated by nerve
injury. This may account for some of the differences
noted between days 3 and 21 gene expression profiles.
Common gene ontologies and transcript cluster sets. Of the
50 genes most up- and downregulated, there were
27 transcripts in common between days 3 and 21.
Among these 27 transcripts, there were 17 common
gene ontologies presented in Table 3 arranged with the
most upregulated transcript first and ending with the
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most downregulated transcript for day 3 post-TIC.
Using the NIH “Process” ontology, common ontologies
included peptide cross-linking, inflammatory response,
chemokine-mediated signaling pathway, immune
system process, innate immune response, defense
response to bacterium, neuropeptide signaling pathway,
G-protein-coupled receptor signaling pathway, signal
transduction, ion transport, positive regulation of transcription by RNA polymerase II, positive regulation of
gene expression, positive regulation of cell proliferation,
biological process, proteolysis, lipid catabolic process,
and lipid metabolic process.
Overall, signal intensities of 1902 and 1392 transcript
cluster sets were significantly different from naı̈ve controls at days 3 and 21 post-TIC injury (p < 0.05), respectively. These transcript cluster sets, regardless of
magnitude or direction, were evaluated in DAVID to
identify enrichments of genes associated with particular
KEGG pathways, biological processes, and molecular
functions at the examined time points. Differentially regulated genes were significantly enriched for 42 KEGG
pathways at days 3 and 21 post-TIC injury (p < 0.05,
data available). Genes associated with the top 10
enriched KEGG pathways at day 3 and the only
KEGG pathway at day 21 are presented in Table 4.
Pathways of particular interest include (1) neuroactive
ligand–receptor interaction, (2) Rap1 signaling pathway,
(3) glutamatergic synapse, and (4) long-term potentiation. There was significant enrichment of genes associated with 54 biological processes and 29 molecular
functions on day 3 post-TIC injury. Thirty biological
processes and 12 molecular functions were identified
from day 21 post-TIC TG (p < 0.05).
The top 10 biological processes and molecular functions are presented in Table 5. Of particular interest on
day 3 are the signal transduction, activation of MAPKK
activity, cell migration, cellular response to interferonalpha biological processes, voltage-gated ion channel
activity, signal transducer activity, GTP binding, histone
methyltransferase activity (H3-K9 specific), transcription factor activity, and sequence-specific DNA binding
molecular functions. The expression changes for day 3
were not unexpected based on previous studies. At day
21, insulin signaling pathway and resistance expression
clusters were upregulated in the TG.

Global acetylation of H3K9 in the TG after TIC injury
Acetylation of H3K9 was decreased in the TG 21 days after TIC
injury. To explore the epigenetic involvement of this TIC
nerve injury model of trigeminal neuropathic pain,
changes in global expression of H3K9 acetylation
(H3K9ac) protein were examined for the V2 TG from
mice at 3 and 21 days post-injury. H3K9ac immunoreactivity appears in the nuclei of neurons (Figure 2(a) to
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Table 1. Genes differentially regulated >50% three days post-TIC injury.
Transcript ID

Gene assignment

Upregulated
17407412
Small proline-rich protein 1A
17360942
Galanin
17231033
Activating transcription factor 3
17244601
Neurotensin
17485098
Mucin 5, subtype B, tracheobronchial
17343170
Trefoil factor 2 (spasmolytic protein 1)
17253215
Solute carrier family 6 (neurotransmitter transporter)
17458514
Neuropeptide Y
17344943
Cysteine-rich secretory protein 3
17483925
Deleted in malignant brain tumors 1
17318815
Apolipoprotein L 11b
17495622
Glycoprotein 2 (zymogen granule membrane)
17268243
Beta-1,4-N-acetyl-galactosaminyl transferase 2
17481378
Cholecystokinin B receptor
17275015
Anterior gradient 2 (Xenopus laevis)
17467973
Regenerating islet-derived 3 gamma
17354074
G protein-coupled receptor 151
17517097
RIKEN cDNA 1600029D21 gene
17225224
Endothelin converting enzyme-like 1
17251091
Myosin, heavy polypeptide 4, skeletal muscle
17522555
Lactotransferrin
17334172
Demilune cell and parotid protein 2
17266851
Schlafen 9
17358749
Lipase, family member N
17497525
A disintegrin and metallopeptidase domain 8
17459309
Immunoglobulin kappa variable 14-126
17216960
Polymeric immunoglobulin receptor
17358724
Lipase, gastric
17524311
Mucin 16
17245231
Lysozyme 1
17438684
Odontogenic, ameloblast asssociated
17496211
ATPase, Caþþ transporting, cardiac muscle, fast twitch 1
17378149
BPI fold containing family B, member 1
17463338
Fibroblast growth factor 23
17392255
Fibronectin leucine rich transmembrane protein 3
17318083
Lymphocyte antigen 6 complex, locus A
17438963
Pro-platelet basic protein
17500195
Steroidogenic acute regulatory protein
17270162
Solute carrier family 4 (anion exchanger), member 1
17531701
Predicted gene, 20317
17296344
Follistatin
17314373
Mucin 19
17254295
Extracellular proteinase inhibitor
17284507
Immunoglobulin heavy chain (gamma polypeptide)
17474621
Creatine kinase, muscle
17273304
Carbonyl reductase 2
17337458
Tripartite motif-containing 10
17467316
Growth arrest and DNA-damage-inducible 45 alpha
17509565
Annexin A10
17547647
Predicted gene 9241
Downregulated
17491349
MAS-related GPR, member B5
17479944
Olfactory receptor 295

Gene symbol

TIC/naı̈ve ratio

p Values

q Values

Sprr1a
Gal
Atf3
Nts
Muc5b
Tff2
Slc6a4
Npy
Crisp3
Dmbt1
Apol11b
Gp2
B4galnt2
Cckbr
Agr2
Reg3g
Gpr151
1600029D21Rik
Ecel1
Myh4
Ltf
Dcpp2
Slfn9
Lipn
Adam8
Igkv14-126
Pigr
Lipf
Muc16
Lyz1
Odam
Atp2a1
Bpifb1
Fgf23
Flrt3
Ly6a
Ppbp
Star
Slc4a1
Gm20317
Fst
Muc19
Expi
Ighg
Ckm
Cbr2
Trim10
Gadd45a
Anxa10
Gm9241

174.86
25.96
7.84
7.32
6.95
6.75
5.25
4.97
4.55
4.32
4.17
4.09
4.08
4.00
3.98
3.96
3.81
3.65
3.59
3.58
3.50
3.49
3.33
3.32
3.29
3.17
3.13
3.10
2.91
2.83
2.83
2.77
2.74
2.68
2.66
2.56
2.56
2.55
2.49
2.48
2.46
2.42
2.41
2.40
2.40
2.36
2.35
2.34
2.33
2.30

4.81E-06
1.52E-05
6.45E-06
2.56E-04
1.59E-01
1.52E-01
1.44E-03
5.66E-04
2.05E-01
3.51E-01
5.74E-02
1.93E-01
2.31E-01
1.03E-04
2.41E-01
1.48E-01
4.54E-04
9.46E-02
1.37E-03
1.01E-01
3.18E-01
2.06E-01
1.55E-02
1.34E-03
6.22E-04
1.09E-01
1.73E-01
3.51E-01
1.62E-01
4.82E-01
2.32E-01
2.88E-01
3.50E-01
6.46E-03
2.22E-04
1.91E-02
3.88E-01
1.28E-03
3.69E-01
1.79E-01
3.95E-03
2.01E-01
4.37E-01
1.66E-01
2.94E-01
1.23E-01
1.53E-01
9.45E-04
1.01E-02
1.93E-02

3.23E-04
5.07E-04
3.23E-04
3.20E-03
3.00E-01
2.96E-01
8.48E-03
5.65E-03
3.22E-01
3.78E-01
1.64E-01
3.18E-01
3.36E-01
1.71E-03
3.45E-01
2.96E-01
5.04E-03
2.36E-01
8.48E-03
2.47E-01
3.70E-01
3.22E-01
5.52E-02
8.48E-03
5.65E-03
2.60E-01
3.09E-01
3.78E-01
3.01E-01
4.92E-01
3.36E-01
3.54E-01
3.78E-01
2.58E-02
3.17E-03
6.24E-02
4.04E-01
8.48E-03
3.93E-01
3.14E-01
1.88E-02
3.22E-01
4.51E-01
3.01E-01
3.54E-01
2.73E-01
2.96E-01
7.47E-03
3.88E-02
6.24E-02

Mrgprb5
Olfr295

0.45
0.49

3.89E-02
1.74E-02

3.89E-02
3.48E-02

Note: The top 50 upregulated and two downregulated genes at the three-day time point after TIC injury are shown compared to the naı̈ve control group
with their p values and a false discovery rate of 5% (q value; n ¼ 6 per group). Bold font indicates genes uniquely expressed on Day 3 but not on Day 21.
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Table 2. Genes differentially regulated >50% 21 days post-TIC injury.
Transcript ID
Upregulated
17407412
17244601
17231033
17481378
17360942
17219639
17362953
17273694
17225224
17463619
17266851
17500195
17421521
17449585
17318083
17264835
17366355
17497637
17285677
17532710
17491349
17458960
17494710
17458439
17230078
17525471
17548752
17286434
17387662
17358749
17358832
17242322
17544295
17483192
17331258
17546316
17285746
17545543
17429512
17489547
17244563
17263765
17212364
17217048
17533462
17467108
17477055
17407400
17448676
17500702

Gene assignment

Gene symbol

TIC/naı̈ve
ratio

p Values

q Values

Small proline-rich protein 1A
Neurotensin
Activating transcription factor 3
Cholecystokinin B receptor
Galanin
Olfactory receptor 418, pseudogene 1
Membrane-spanning 4-domains,
subfamily A, member 7
Pro-opiomelanocortin-alpha
Endothelin converting enzyme-like 1
Proline rich protein 2
Schlafen 9
Steroidogenic acute regulatory protein
Predicted gene 13154
Betacellulin, epidermal growth
factor family member
Lymphocyte antigen 6 complex, locus A
CD68 antigen
Component of Sp100-rs
Olfactory receptor 524
Histone cluster 1, H2ao
Predicted gene 14347
MAS-related GPR, member B5
Vomeronasal 1 receptor 20
Olfactory receptor 707
Glycoprotein (transmembrane) nmb
Myeloid cell nuclear differentiation antigen
Predicted gene 3434
Transmembrane protein 202
Serine (or cysteine) peptidase inhibitor,
clade B, member 9g
Olfactory receptor 1054
Lipase, family member N
Interferon-induced protein with
tetratricopeptide repeats 1
Predicted gene 9507
Serine-rich, secreted, X-linked
Seizure related 6 homolog like 2
Olfactory receptor 197
Eukaryotic translation initiation
factor 2, subunit 3
Histone cluster 1, H2bn
Predicted gene 16390
MicroRNA 30c-1
Predicted gene 6725
Citrate synthase like
Solute carrier family 47, member 1
RIKEN cDNA 1500015O10 gene
RIKEN cDNA 5430435G22 gene
Predicted gene 5382
LSM5 homolog, U6 small nuclear
RNA associated (S. cerevisiae)
Expressed sequence EU599041
Small proline-rich protein 1B
Predicted gene 5868
A disintegrin and metallopeptidase
domain 25 (testase 2)

Sprr1a
Nts
Atf3
Cckbr
Gal
Olfr418-ps1
Ms4a7

15.44
4.69
2.74
2.72
2.40
2.25
2.16

4.46E-04
1.32E-03
9.49E-04
9.17E-04
3.76E-02
2.05E-03
2.78E-03

1.12E-02
1.89E-02
1.58E-02
1.58E-02
7.10E-02
2.28E-02
2.53E-02

Pomc
Ecel1
Prp2
Slfn9
Star
Gm13154
Btc

2.06
2.00
1.86
1.83
1.83
1.79
1.77

4.60E-01
3.19E-02
1.38E-01
1.62E-01
1.43E-02
1.66E-04
2.87E-04

4.70E-01
6.77E-02
1.75E-01
1.86E-01
4.76E-02
1.08E-02
1.08E-02

Ly6a
Cd68
Csprs
Olfr524
Hist1h2ao
Gm14347
Mrgprb5
Vmn1r20
Olfr707
Gpnmb
Mnda
Gm3434
Tmem202
Serpinb9g

1.76
1.76
1.72
1.71
1.71
1.67
1.67
1.66
1.65
1.65
1.65
1.63
1.61
1.61

1.16E-01
2.87E-02
3.62E-02
2.10E-02
6.48E-03
7.65E-03
1.51E-01
7.18E-02
2.78E-02
2.44E-02
1.71E-01
7.33E-03
4.93E-02
2.57E-02

1.52E-01
6.74E-02
7.05E-02
5.82E-02
3.79E-02
3.82E-02
1.80E-01
1.04E-01
6.74E-02
6.41E-02
1.86E-01
3.82E-02
8.22E-02
6.43E-02

Olfr1054
Lipn
Ifit1

1.60
1.60
1.60

6.03E-02
9.59E-02
3.32E-02

9.42E-02
1.31E-01
6.77E-02

Gm9507
Srsx
Sez6l2
Olfr197
Eif2s3y

1.59
1.59
1.59
1.59
1.58

6.19E-03
1.03E-01
4.81E-01
1.78E-03
1.55E-01

3.79E-02
1.37E-01
4.84E-01
2.22E-02
1.82E-01

Hist1h2bn
Gm16390
Mir30c-1
Gm6725
Csl
Slc47a1
1500015O10Rik
5430435G22Rik
Gm5382
Lsm5

1.58
1.57
1.57
1.57
1.56
1.56
1.55
1.55
1.55
1.54

6.99E-02
3.01E-02
2.53E-01
2.01E-02
1.57E-02
2.14E-01
1.38E-01
6.03E-03
1.63E-01
2.46E-03

1.04E-01
6.74E-02
2.61E-01
5.81E-02
4.91E-02
2.27E-01
1.75E-01
3.79E-02
1.86E-01
2.46E-02

EU599041
Sprr1b
Gm5868
Adam25

1.53
1.52
1.52
1.52

7.16E-02
1.48E-02
4.25E-02
9.92E-03

1.04E-01
4.77E-02
7.58E-02
4.06E-02

(continued)
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Table 2. Continued
Transcript ID
Downregulated
17483925
17245231
17358724
17378149
17522555
17254295
17485098
17305520
17343170
17502789
17408897
17268243
17326075
17312219
17399823
17407363
17495622
17270162
17522369
17337706
17496211
17275015
17251046
17350267
17284354
17371296
17485246
17303874
17372662
17396152
17424880
17235011
17497704
17232453
17246412
17474621
17243910
17514553
17531482
17438963
17284334
17365803
17490245
17385099
17487759
17302279
17214476
17229851
17484587
17294816

Gene assignment

Gene symbol

TIC/naı̈ve
ratio

p Values

q Values

Deleted in malignant brain tumors 1
Lysozyme 1
Lipase, gastric
BPI fold containing family B, member 1
Lactotransferrin
Extracellular proteinase inhibitor
Mucin 5, subtype B, tracheobronchial
Eosinophil-associated, ribonuclease
A family, member 1
Trefoil factor 2 (spasmolytic protein 1)
Glycophorin A
Chitinase 3-like 3
Beta-1,4-N-acetyl-galactosaminyl transferase 2
Resistin like gamma
Lymphocyte antigen 6 complex, locus G
S100 calcium binding protein A8 (calgranulin A)
S100 calcium binding protein A9 (calgranulin B)
Glycoprotein 2 (zymogen granule membrane)
Solute carrier family 4 (anion exchanger),member 1
Neutrophilic granule protein
Rhesus blood group-associated A glycoprotein
ATPase, Caþþ transporting, cardiac muscle, fast twitch 1
Anterior gradient 2 (Xenopus laevis)
Myosin, heavy polypeptide 1, skeletal muscle, adult
Myotilin
Immunoglobulin heavy chain (J558 family)
Xin actin-binding repeat containing 2
Troponin T3, skeletal, fast
Myozenin 1
Proteoglycan 2, bone marrow
Carbonic anhydrase 3
Predicted gene, 19980
Elastase, neutrophil expressed
Cytochrome c oxidase, subunit VIIIb
Triadin
Olfactory receptor 773
Creatine kinase, muscle
Myosin binding protein C, slow-type
Matrix metallopeptidase 8
Cathelicidin antimicrobial peptide
Pro-platelet basic protein
Immunoglobulin heavy chain (gamma polypeptide)
Nebulin-related anchoring protein
Myosin binding protein C, fast-type
Nebulin
CD177 antigen
Olfactomedin 4
Desmin
calsequestrin 1
Cytochrome P450, family 2,
subfamily e, polypeptide 1
Creatine kinase, mitochondrial 2

Dmbt1
Lyz1
Lipf
Bpifb1
Ltf
Expi
Muc5b
Ear1

0.11
0.12
0.14
0.16
0.18
0.18
0.20
0.20

1.77E-01
1.68E-01
1.27E-01
1.07E-01
1.83E-01
1.51E-01
2.30E-01
2.71E-01

4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01

Tff2
Gypa
Chi3l3
B4galnt2
Retnlg
Ly6g
S100a8
S100a9
Gp2
Slc4a1
Ngp
Rhag
Atp2a1
Agr2
Myh1
Myot
Igh-VJ558
Xirp2
Tnnt3
Myoz1
Prg2
Car3
Gm19980
Elane
Cox8b
Trdn
Olfr773
Ckm
Mybpc1
Mmp8
Camp
Ppbp
Ighg
Nrap
Mybpc2
Neb
Cd177
Olfm4
Des
Casq1
Cyp2e1

0.24
0.27
0.30
0.32
0.33
0.34
0.34
0.35
0.35
0.35
0.36
0.36
0.37
0.37
0.38
0.38
0.39
0.39
0.40
0.40
0.41
0.41
0.41
0.41
0.42
0.42
0.42
0.43
0.43
0.44
0.45
0.45
0.45
0.45
0.45
0.46
0.46
0.46
0.47
0.47
0.47

2.66E-01
2.85E-01
2.89E-01
3.19E-01
2.50E-01
3.49E-01
3.40E-01
2.65E-01
3.23E-01
3.10E-01
3.51E-01
1.71E-01
2.94E-01
3.89E-01
3.71E-01
2.29E-01
2.14E-01
1.64E-01
2.88E-01
2.41E-01
2.81E-01
2.98E-01
1.01E-01
3.23E-01
5.12E-02
2.19E-01
2.52E-02
3.07E-01
2.22E-01
3.49E-01
3.93E-01
4.64E-01
1.68E-01
9.83E-02
1.72E-01
1.73E-01
2.38E-01
2.44E-01
1.84E-01
1.23E-01
3.60E-01

4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.11E-01
4.08E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.11E-01
4.64E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01
4.03E-01

Ckmt2

0.47

1.58E-01

4.03E-01

Note: The top 50 upregulated and downregulated genes at the 21-day time point after TIC injury are shown compared to the naı̈ve control group with their
p values and a false discovery rate of 5% (q value; n ¼ 6 per group). TIC: trigeminal nerve injury. Bold font indicates genes uniquely expressed on Day 21 but
not on Day 3.
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Table 3. Overlapping gene ontology for days 3 and 21 post-TIC.
Gene ontology

Number
of genes

Gene
Symbol

Regulated
expression day 3

Regulated
expression day 21

Nerve regeneration/peptide cross-linking
Inflammatory response

1
2

Chemokine-mediated signaling pathway

2

Immune system process

2

Innate immune response

3

Defense response to bacterium

3

Ion transport

2

Neuropeptide signaling pathway

2

G-protein-coupled receptor signaling pathway

3

Signal transduction

2

Positive regulation of transcription by RNA polymerase II

2

Positive regulation of gene expression

3

Positive regulation of cell proliferation

3

Biological process

2

Proteolysis

2

Lipid catabolic process

2

Lipid metabolic process

2

Sprr1a
Gal
Ppbp
Tff2
Ppbp
Ltf
Bpifb1
Dmbt1
Bpifb1
Ighg
Muc5b
Lyz1
Ighg
Ltf
Slc4a1
Gal
Ecel1
Nts
Cckbr
Ppbp
Mrgprb5
Cckbr
Mrgprb5
Gal
Atf3
Atf3
Agr2
Star
Atf3
Tff2
Cckbr
Slfn9
Lipn
Ecel1
Ltf
Lipn
Lipf
Lipn
Lipf

Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Downregulated
Upregulated
Downregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated

Upregulated
Upregulated
Downregulated
Downregulated
Downregulated
Downregulated
Downregulated
Downregulated
Downregulated
Downregulated
Downregulated
Downregulated
Downregulated
Downregulated
Downregulated
Upregulated
Upregulated
Upregulated
Upregulated
Downregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Upregulated
Downregulated
Upregulated
Upregulated
Downregulated
Upregulated
Upregulated
Upregulated
Upregulated
Downregulated
Upregulated
Downregulated
Upregulated
Downregulated

Seventeen gene ontologies were found in common for days 3 and 21 post-TIC.

(h)) and non-neuronal profiles (Figure 2(j) and (k)). The
H3K9ac protein, as determined by immunofluorescence
staining, was expressed predominately in medium- and
small-sized neurons (Figure 2(g) and (h)). At 3-day postinjury time point, the percentage of H3K9ac-positive
neurons did not differ significantly from that of the
naı̈ve group (80.1% of total neurons after TIC injury
vs. 83.5% of total neurons in naı̈ve mice; n ¼ 3 per
group, p > 0.05; total neuron count ¼ 10,019) (Figure 2
(i), top). In contrast, the percentage of H3K9ac-positive
neurons decreased significantly (41.5% of total neurons
in the ipsilateral TG after TIC vs. 78% of total neurons

in naı̈ve mice; n ¼ 3 per group, p  0.01; total neuron
count ¼ 6,890) at day 21 post-nerve injury (Figure 2(i),
bottom). The percentage of total neurons expressing
H3K9ac on the contralateral side TG in mice with TIC
injury was not significantly different from that of naı̈ve
mice (data not shown). These data provide clear evidence of epigenetic modulation in the TG limited to
the side of the TIC injury persisting at day 21 postnerve injury time point.
Minimal dual labeling of H3K9ac in TG satellite glial cells. To
further investigate the acetylation of H3K9 in non-
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Table 4. KEGG pathways.
Term

Count

Gene Symbols

p Value

Three days post-TIC
mmu04713:Circadian entrainment

18

Adcy1, Adcy5, Adcy8, Calm4, Camk2a, Camk2b, Gnai1, Gnai2,
Gnaq, Gnb2, Gria3, Gria4, Grin1, Grin2a, Itpr1, Plcb1,
Plcb3, Prkg2
Adra2c, Avpr1a, C3ar1, Cckar, Cckbr, Chrm2, Chrm5, Chrna6,
Cysltr2, F2r, Gabra6, Gabrb2, Gabrg2, Gria3, Gria4, Grin1,
Grin2a, Grin3a, Htr1f, Htr4, Lpar3, Ltb4r2, Mc2r, Mc4r, P2rx2,
P2ry13, P2ry6, Ptgdr, Ptgir, S1pr1, S1pr2, Taar2, Taar7e, Taar8b,
Taar9, Thra
Adcy1, Adcy5, Adcy8, Calm4, Csf1, Csf1r, F2r, Fgf11, Fgf2, Fgf23,
Fgf3, Figf, Gnai1, Gnai2, Gnaq, Grin1, Grin2a, Hgf, Igf1r, Itgb1,
Lpar3, Lpar5, Magi2, Pard6a, Pfn1, Plcb1, Plcb3, Rac1, Tln2
Adcy1, Adcy5, Adcy8, Gls, Gnai1, Gnai2, Gnaq, Gnb2, Gria3,
Gria4, Grin1, Grin2a, Grin3a, Homer1, Itpr1, Plcb1, Plcb3,
Pld2, Slc1a7
Adcy1, Adcy5, Adcy8, Calm4, Camk2a, Camk2b, Cckbr, Gnai1,
Gnai2, Gnaq, Itpr1, Plcb1, Plcb3, Sst
Adcy1, Adcy5, Adcy8, Faah, Gabra6, Gabrb2, Gabrg2, Gnai1,
Gnai2, Gnaq, Gnb2, Gria3, Gria4, Itpr1, Plcb1, Plcb3, Rims1
Cyp24a1, Dhcr24, Dhcr7, Ebp, Lss, Soat1, Soat2
Adcy1, Adcy8, Calm4, Camk2a, Camk2b, Gnaq, Grin1, Grin2a,
Itpr1, Plcb1, Plcb3, Rps6ka1, Rps6ka2
Adcy1, Adcy5, Adcy8, Gnai1, Gnai2, Gnaq, Itpr1, Plcb1, Plcb3,
Prkg2, Tuba1c, Tubb2b, Tubb3, Tubb5, Tubb6
Adcy1, Adcy5, Adcy8, Calm4, Camk1, Camk2a, Camk2b, Gnaq,
Hsd3b1, Itpr1, Mc2r, Plcb1, Plcb3, Prkce, Star

1.80E-04

mmu04080:Neuroactive
ligand-receptor interaction

36

mmu04015:Rap1 signaling pathway

29

mmu04724:Glutamatergic synapse

19

mmu04971:Gastric acid secretion

14

mmu04723:Retrograde
endocannabinoid signaling
mmu00100:Steroid biosynthesis
mmu04720:Long-term potentiation

17

mmu04540:Gap junction

15

mmu04925:Aldosterone
synthesis and secretion
21 Days post-TIC
mmu04910:Insulin signaling pathway

15

7
13

14

Phkg1, Rps6kb1, Pck1, Srebf1, Lipe, Trip10, Pik3r2, Hk1, Socs4,
Acacb, Phka1, Sh2b2, Rheb, Fasn

2.06E-04

3.14E-04

4.41E-04

6.88E-04
9.83E-04
9.90E-04
1.03E-03
1.26E-03
1.26E-03

9.64E-03

Note: Genes associated with the top 10 enriched KEGG pathways at days 3 and 21. Note that the upregulated genes are underlined in the third column of
the table. KEGG: Kyoto Encyclopedia of Genes and Genomes.

neuronal cells, the satellite glial cells of TG were dual
stained. For positive identification of satellite glial cells,
an antibody for the glial marker glutamine synthetase
(GS) was used. This key enzyme catalyzes the amidation
of glutamate to glutamine.
Its localization is restricted to glia cells in the
brain,24–26 as well as satellite glial cells and Schwann
cells in DRG and TG sensory ganglia.27–30
Neurons in the TG are sensory homologues to
those of the DRG. To identify the relative size distribution of TG neurons in naı̈ve mice, the diameters
were analyzed using MetaMorph offline software
(5,119 neurons, n ¼ 4). Based on diameter, three
groups of neurons were classified as small (<20 mm)
with 9.9% frequency, medium (20–40 mm) with 83.4%
frequency, or large (>40 mm) with 6.7% frequency.
About 93% of neurons in the TG are small-sized neurons (<20 mm) and medium-sized neurons (20–40mm)
which likely mediate nociception and would require
increased synthesis of the neuropeptides and neurotransmitters released in pathological conditions. The smallest

diameter neurons were 11 mm. The maximum diameter
of the large-sized TG neurons was 60 mm which was
slightly smaller than that of neurons in the DRG.29
Occasionally, neurons with diameters of > 61 mm were
observed (0.12% frequency). Neuron sizes in mice were
similar to those previously reported for TG of mice and
Wistar rats, except unlike the rat which is reported to
have more larger neurons and have more in the left TG
than the right,30 similar percentage distributions were
observed on left and right sides of these study mice
(Figure 2, bottom).

HDACi’s prevented development of mechanical
hypersensitivity
The fact that global acetylation of H3K9 was decreased
in ipsilateral TG neurons 21 days post-TIC injury suggested that reduced H3K9 acetylation contributes to the
observed dysregulated gene expression resulting in persistence of pain. Therefore, we explored whether inhibiting histone deacetylase (HDAC) activity would block
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Table 5. Top 10 biological process and molecular function terms.
Term

Count

Three days post-TIC injury-enriched “biological process” terms of differentially expressed genes
GO:0007399nervous system development
44
GO:0045124regulation of bone resorption
5
GO:0050790regulation of catalytic activity
8
GO:0051262protein tetramerization
10
GO:0007165signal transduction
112
GO:0007264small GTPase mediated signal transduction
29
GO:0016197endosomal transport
9
GO:0051260protein homooligomerization
25
GO:0000186activation of MAPKK activity
8
GO:0034765regulation of ion transmembrane transport
19
Three days post-TIC injury enriched "molecular function” terms of differentially expressed genes
GO:0043236laminin binding
9
GO:0005216ion channel activity
25
GO:0042803protein homodimerization activity
79
GO:0005251delayed rectifier potassium channel activity
9
GO:0071933Arp2/3 complex binding
5
GO:0005244voltage-gated ion channel activity
19
GO:0004871signal transducer activity
62
GO:0051015actin filament binding
18
GO:1901981phosphatidylinositol phosphate binding
4
GO:0001664G-protein-coupled receptor binding
11
21 Days post-TIC injury enriched “biological process” terms of differentially expressed genes
GO:0048566embryonic digestive tract development
6
GO:0016477cell migration
20
GO:0007049cell cycle
45
GO:0014044Schwann cell development
4
GO:0007283spermatogenesis
31
GO:0035458cellular response to interferon-beta
7
GO:1902953positive regulation of ER to Golgi vesicle-mediated transport
3
GO:0006364rRNA processing
13
GO:0035457cellular response to interferon-alpha
4
GO:0032868response to insulin
9
21 Days post-TIC injury enriched “molecular function” terms of differentially expressed genes
GO:0046872metal ion binding
185
GO:0005525GTP binding
29
GO:0003676nucleic acid binding
76
GO:0005515protein binding
219
GO:0046974histone methyltransferase activity (H3-K9 specific)
3
GO:0043237laminin-1 binding
3
GO:0003700transcription factor activity, sequence-specific DNA binding
55
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding
18
GO:0019789SUMO transferase activity
4
GO:0004252serine-type endopeptidase activity
17

p Value
4.38E-04
1.13E-03
1.26E-03
1.31E-03
1.42E-03
2.32E-03
3.18E-03
3.27E-03
3.76E-03
3.93E-03
2.16E-04
4.52E-04
5.48E-04
1.01E-03
1.96E-03
3.84E-03
4.93E-03
7.43E-03
8.68E-03
1.00E-02
1.15E-03
1.65E-03
3.55E-03
9.63E-03
9.91E-03
1.16E-02
1.24E-02
1.53E-02
1.65E-02
1.77E-02
1.53E-02
1.59E-02
1.67E-02
2.62E-02
2.97E-02
2.97E-02
3.39E-02
3.46E-02
3.76E-02
4.56E-02

Note: Post-TIC injury differentially expressed genes at days 3 and 21 were enriched for the indicated processes and functions.

the development of mechanical hypersensitivity after
TIC nerve injury. In the second cohort, the time course
of whisker pad hypersensitivity was tested through day
28 post-TIC nerve injury. Two class I HDACi’si, SAHA
and MS-275, were used to determine their effect on the
hypersensitized responses to the ipsilateral whisker pad
stimulation. Figure 3 shows the average mechanical
threshold of the ipsilateral side whisker pad for the

cohort receiving daily HDACi treatments initiated five
days before and continued seven days after TIC surgery.
The initial average baseline threshold values of all mice
was 2.60  0.54 g. Mice were then distributed evenly to
treatment groups, such that all groups consisted of three
mice with high baselines and two with moderate baselines (n ¼ 5 per group). The mechanical threshold after
TIC injury of the vehicle-treated group decreased 98%
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Figure 2 Trigeminal nerve injury leads to significant decrease in H3K9 acetylation of trigeminal ganglia (TG) neurons 21 days after injury
compared to naı̈ves. Expression of H3K9ac (a, green) and neuronal marker NeuN (b, red) in TG neurons of a naı̈ve mouse is shown as a
merged image in (c). Expression of H3K9ac (d) and NeuN (e) in TG of a mouse with TIC nerve injury at the 21-day time point is shown as
a merged image in (f). Neurons double labeled with H3K9ac appear orange (white arrows). Enlarged images in (g) and (h) are from the
framed areas in panels (c) and (f), respectively. The bar graph (i) shows the percentage of TG neurons expressing H3K9ac (n ¼ 3 per group,
6890 neurons counted) (*** p  0.01, t-test). Scale bar ¼ 200 lm. H3K9ac in non-neuronal TG cells. H3K9ac immunoreactivity was
localized on the nuclei of neurons and non-neuronal structures (red). Satellite glial cells (and potentially epithelial cells and Schwann cells)
were stained for glutamine synthetase in the TG (green). Example of dual labeling of H3K9ac (red) and non-neuronal marker glutamine
synthetase (green) in TG from a naı̈ve mouse (j) and a TIC injury mouse (k) at 21 days. Some of the satellite glial cells are indicated with
white arrows. H3K9ac immunoreactivity visually appears more prevalent in TG from naı̈ve mice than in the trigeminal nerve-injured mice.
Bar ¼ 100 mm. Nerve injury decreases H3K9ac, alters transcription, and can increase pain. The summary diagram (l) depicts the relationship of nerve injury pain to H3K9ac decrease, altered transcription, and resultant further increase in pain. Trigeminal ganglia neuronal
counts and size distribution in mice. A total of 5119 TG neurons were counted and measured from three naı̈ve mice (m). The data show
the similarity in the size distribution for the left and right TG in the male BALB/C mice. TIC: trigeminal nerve injury.
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Figure 3. Effect of preemptive HDAC inhibitors on mechanical thresholds. The average 50% mechanical thresholds were determined for
the ipsilateral side whisker pads of mice TIC injury with/without HDAC inhibitor treatment. Responses over time for each of the three
initially matched groups (i.e. vehicle, SAHA and MS275; n ¼ 5 per group) were compared to baseline. By day 21 and 28, the mechanical
thresholds of mice with TIC injury treated preemptively with SAHA or MS275 were no longer significantly decreased compared to
baseline levels and were significantly different from mice with TIC treated with vehicle. Note that symbols of significance for vehicle and
MS275 groups are located below data points while those for SAHA are located above (n = 5 per group, * ¼ vs. baseline; # ¼ vs. TIC +
vehicle; *p < 0.05; **p < 0.01; ***p <0.001; #p < 0.05; ##p < 0.01; ###p<0.001, two-way ANOVA, Tukey’s multiple comparisons test).
SAHA: suberanilohydroxamic acid.

to 0.052  0.03 g on day 3 post-nerve injury, indicating
increased hypersensitivity due to the nerve injury. Their
decreased mechanical threshold continued through day
28 post-surgery (0.05  0.019 g). Responses of two naı̈ve
mice receiving vehicle, serving only as comparison to the
three TIC groups, did not fluctuate from baseline levels
through day 28 post-surgery.
Beginning three days post-surgery, mice with TIC
nerve injury treated pre-emptively with the SAHA
HDACi had reduced mechanical thresholds as well as
on day 7 post-surgery (0.66  0.20 g) (Figure 3). By
day 14, mechanical thresholds significantly increased
(1.27  0.15 g) and remained elevated through day 21
(1.17  0.11 g), indicating attenuation of the mechanical
hypersensitivity. By day 28 post-nerve injury, the
mechanical thresholds were equivalent to the vehicle
control group without TIC (2.07  0. 0.39 g, p > 0.05;
two-way ANOVA, Tukey’s multiple comparisons test).
Compared to the vehicle-treated TIC injury group, this
was a statistically significant increase in the mechanical
threshold (p  0.01; two-way ANOVA, Tukey’s multiple
comparisons test; n ¼ 5 per group).
Mechanical thresholds in mice with TIC injury
treated pre-emptively with MS275 remained near presurgery baseline thresholds similar to the other groups
(2.60  0.54 g; n ¼ 5 per group) (Figure 3). While a
decreased mechanical threshold (0.24  0.13 g) was evident on day 3 post-surgery indicating that the TIC injury

procedure was successful, the mechanical threshold was
increased to 2.39  0.44 g on post-surgery day 28. The
final average threshold was similar to naı̈ve mice (2.50
 0.50 g, p > 0.05; two-way ANOVA, Tukey’s multiple
comparisons test). The mechanical threshold for the
MS275-treated group was significantly increased compared to vehicle-treated TIC injury mice (p  0.001).

qPCR authentication with and without HDACi’s
Authentication by qPCR demonstrated that average
Sprr1a, Gal, and Atf3 gene expression levels three-days
post-TIC were increased 650-, 116- and 22-fold; and they
were increased 206-, 4.8- and 4.8-fold 21 days post-TIC
(Figure 4). In addition to Gal, other neuropeptides, neurotensin (Nts), and neuropeptide Y (Npy) were increased
post-TIC injury > seven- and fourfold, respectively, after
three days. By 28 days, relative gene expression for Gal
and Atf3 in mice with TIC was the same as in naı̈ve mice
with or without HDACi’s, while Sprr1a remained elevated 10-fold.

Discussion
An important finding is that preemptive administration
of two HDACi’s, SAHA and MS-275, prevented development of persistent mechanical hypersensitivity after
trigeminal nerve injury. In the present study, the TIC
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Figure 4. Relative mRNA levels are shown at days 3, 21, and 28 for Sprr1a (a), Gal (b), and Atf3 (c) in TG from mice with and without
TIC, with and without the HDAC inhibitors or vehicle. The gene expression at days 3 and 21 is in contrast to day 28. By 28 days, relative
gene expression for Gal and Atf3 in mice with TIC was the same as in naı̈ve mice with or without HDACi’s, while Sprr1a remained elevated
10-fold. SAHA: suberanilohydroxamic acid; TIC: trigeminal nerve injury.

nerve injury mouse model was also employed to determine the expression and epigenetic modifications in TG
associated with orofacial neuropathic pain at two time
points. Following TIC injury, RAG genes were upregulated early in the course of injury repair, and remained
upregulated three weeks post-TIC injury. qPCR determined that Sprr1a mRNA expression which was greatly
elevated 3,650-fold three days after nerve injury
remained elevated at 28 days, while expression of the
two RAGs, Atf3 and Gal, had returned to control
levels. Although no detectable change in global acetylation of H3K9 was evident on day 3, it was significantly
decreased in ipsilateral TG neurons by day 21. The most
straightforward interpretation is that differentially
expressed genes at day 3 are not yet affected but by

day 21 are likely affected by cumulative histone deacetylation. Several common and many uniquely expressed
genes were discovered in the TG comparing the day 3
and day 21 post-nerve injury time points. These findings
are consistent with a windup phase of histone deacetylation during the first three weeks following TIC injury
and indicate TG neurons are receptive to epigenetic
modifications that may be associated with critical
aspects of the pain response.

Animal model to examine epigenetic changes
over time
The TIC nerve injury mouse model is ideal to determine
epigenetic changes over time. The model was devised to

Danaher et al.
provide a reliable model of orofacial neuropathic pain
developing quickly and persisting long term.14,15 The
decrease in mechanical threshold induced on the whisker
pad ipsilateral to the TIC injury indicates an increase in
mechanical hypersensitivity or allodynia. The hypersensitivity persists steadily through the 28-day trial without
recovery. Both whisker pads of the naı̈ve mice as well as
the contralateral side whisker pad in mice with TIC
injury show no mechanical threshold changes further
indicating the effectiveness and reliability of the TIC
model. Our previous studies document the decrease in
the mechanical threshold can persist at least through
week 21 after TIC injury.14

Differential gene expression in the ipsilateral
trigeminal ganglia post-TIC nerve injury
It is interesting to speculate that epigenetic mechanisms
contribute to the continued overexpression of these
genes long after others have returned to constitutive
levels and may be contributing to persistent pain
states. Several genes were differentially expressed in
TGs after TIC injury at both the 3- and 21-day time
points reflecting the dysregulation in this orofacial neuropathic pain model. A number of published microarray
studies have addressed similar gene expression patterns
in DRG after sciatic nerve injury.31–34 Genes typically
dysregulated in pain conditions including injury biomarkers (e.g. Atf3 and Sprr1a) and neuropeptides (Gal
and Npy) were also expressed in the TIC model after
trigeminal nerve injury. Not unexpectedly since glutamate is a key pain neuroactivator, dysregulated genes
associated with glutamatergic synapses, long-term
potentiation, gap junction, and neuroactive ligand–
receptor interactions were abundant in the KEGG pathway analysis. Several studies have identified gene expression in TG of both humans and rodents35–37; however,
sequential expression over time after trigeminal nerve
injury has not been reported. One point made in these
previous studies is that the gene expression in TG is
unique in comparison to DRG, particularly in the
human for expression of migraine genes.
Genes encoding inflammatory mediators (Cd68, Ccl2,
Cxcl10, Cxcl13), ion channel subunits (e.g. Cacna2d1,
Kcnc2), and growth factors (Vgf) are also reported to
increase after peripheral nerve injury. Interestingly,
other inflammatory cell-related genes (CD177, Igkv14126, IgLy6a, Ly6a, Ighg) not reported previously were
expressed after trigeminal nerve injury.

Biological processes and functions of differentially
expressed genes
Three days post-TIC nerve injury. Thirty-two genes were significantly (p < 0.05) upregulated in ipsilateral TG genes
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three days post-TIC injury. The three most upregulated
genes, Sprr1a (up 174-fold), Gal (up 26-fold), and Atf3
(up 8-fold), are nerve RAGs that are activated following
peripheral nerve injury.38
Atf3, a member of the ATF/CREB family of basic
leucine zipper domain (bZIP) transcription factors, is
normally expressed at low levels but is rapidly activated
in sensory, sympathetic, and motor neurons by stress
stimuli after peripheral nerve injury, but not after central
injury which has much less reparative ability.39,40
Overexpression of Atf3, as part of the inducible nerve
RAG response, along with its “effector” RAGs, Sprr1a,
and Gal, has been observed previously following both
facial nerve damage41 and sciatic nerve injury42 in mice.
Atf3 mutant mice have decreased neurite outgrowth on
primary DRG neurons.41
Sprr1a is one of a group of epithelial differentiation
genes including s100c and p21/waf that are co-induced in
neurons by axotomy where it is thought to stimulate the
extension of axons via regulation of actin-based motility
in growth cone ruffles.43 Although SPRR1A is not
detected in naı̈ve DRGs or peripheral nerves, it is
intensely detected in DRGs and nerves following peripheral sciatic nerve injury.44 It is only minimally detected
following injury of centrally projecting branches of
DRG neurons.
Galanin is a neuropeptide with widespread distribution in the central and peripheral nervous system.45
Although treatment with exogenous galanin promotes
nerve regeneration,45,46 it demonstrates both facilitatory
and inhibitory effects on nociception, depending on pain
model persistence, dose, and mode of delivery.47
In addition to the Rap1 signaling pathway (part of
the RAS superfamily), many other interesting gene clusters were significantly enriched for KEGG pathways and
differentially regulated at three days post-nerve injury in
this study. Aldosterone injection (i.pl. or i.t), for example, induces rapid kinase signaling cascades in the cytoplasm, including activation of another RAS signaling
pathway pain signaling responder, extracellular
stimulus-regulated kinase 1/2 (ERK1/2), increasing activation of DRGs in vitro and mechanical allodynia
in vivo.29,48
The neuroactivator, glutamate synapse, and longterm potentiation clusters were upregulated though not
unexpectedly during persistent pain, as they underlie
short- and long-term synapse formation and neurogenesis.49 The upregulated retrograde endocannabinoid
signaling cluster would be a factor in endogenous
pain control.
21 Days post-TIC injury. Despite the finding that transcription levels of most genes significantly upregulated at
three days are returned to constitutive levels by 21
days post-TIC nerve injury (25 of 32 genes), the three
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RAGs,
Sprr1a,
Atf3,
and
Gal,
remained
upregulated > 15-, 2.7-, and 2.4-fold three weeks later.
The continued over-expression of RAGs is consistent
with the concept that these epigenetic mechanisms play
an important role in the persistence of trigeminal injuryinduced nerve regeneration and allodynia.44,50 Likewise,
this suggests the neuroplasticity in peripheral nerves is
continuing though perhaps not in an adaptive manner
since hypersensitivity in this model persists for at least
six months.14,15
The notable increase in expression of insulin signaling
pathway and resistance clusters at 21 days post-nerve
injury may reflect the requirement for insulin in axon
extension, viability, and repair.51,52 Insulin signaling in
neuronal DRG perikarya has been shown to upregulate
insulin receptor, drive distal sensory axon regrowth,
rescue retrograde alterations of axons, and alter axon
calcitonin gene-related peptide expression in regenerating sprouts.51 At day 21 post-nerve injury, insulin signaling pathway and resistance expression clusters are
also reflective of the trophic satellite glial cell support
for the ongoing neuronal repair. Listed with the gastric
acid secretion cluster is phosphoinositide-specificphospholipase Cb, which is the main effector of Gaq
stimulation coupling numerous pain-related neurotransmitter receptors and hormones to post-transcriptional
gene regulation.53
Molecules encoded by genes dysregulated 21 days
post-TIC nerve injury have a variety of molecular functions including those involved in binding metal ion (e.g.
Cacna2d1 and Kcnc2), proteins (SUMO transferase,
serine-type endopeptidase), laminin-1, GTP, sequencespecific DNA (H3K9, RNA polymerase II regulatory
region sequence-specific, and transcription factor activity), and nucleic acids. Nuclei acids released during
mechanical nerve trauma are highly pro-inflammatory
resulting in further tissue damage due to their excessive
stimulation of the immune response. Endogenous binding of released nucleic acid would enhance reparative
processes in the local environment.

Global acetylation of H3K9 decreased in the
ipsilateral trigeminal ganglia at 3 weeks
The H3K9ac protein was expressed in the nuclei of neurons and the majority of non-neuronal profiles. Only a
minority of the GS-labeled satellite glial cells in the TG
demonstrated co-labeling with H3K9 acetylation protein
after TIC nerve injury. Further investigation is needed to
explore the non-neuronal cells in the TG expressing
H3K9ac and the impact of orofacial neuropathic pain
on other glia and endothelial cells in the TG and brainstem (such as Schwann cells, oligodendrocytes, astrocytes, and ependymal cells) to fully understand the
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epigenetic mechanisms involved in the persistence of
nociceptive pathway activation leading to chronic pain.
The global HDAC immunohistochemistry decrease at
day 21, though not much affected at day 3, provides
support that epigenetic modulation through histone
deacetylation contributes to the maintenance of pain
after tissue healing.

Diminished hypersensitivity after preemptive
treatment with HDACi’s
As it is reported that HDACi needs to be administered
five days prior to the nerve injury surgery to have an
analgesic effect,5 this same treatment regimen was followed in the present study. The HDACi’s SAHA and
MS-275 used preemptively in this study had the ability
to prevent the development of persistent orofacial neuropathic pain. Hypersensitivity reversed to baseline three
weeks after TIC in mice receiving HDACi’s preemptively. The three-week time point ostensibly coincides with
the completion of tissue repair from the TIC nerve injury
surgery. This further supports a role for HDAC deacetylation following TIC injury and is an indicator that
epigenetic modulation is a major contributor to persisting neuropathic pain.
Khangura et al. have reviewed numerous studies identifying the potential of HDACi’s to restore nociceptive
thresholds by increasing histone acetylation, while other
studies reported that histone acetylation promotes
pain.54 Evidence was provided for both nerve injury
and inflammatory pain models, primarily examining sciatic nerve and spinal cord plasticity. It has been shown
that neuron-restrictive silencer factor expression upregulated in DRG neurons after peripheral nerve injury is
mediated through epigenetic mechanisms causing Cfiber dysfunction and promoting neuropathic pain.55-57
HDACi’s have been shown to relieve acute formalin
pain-related behaviors by upregulating mGlu2 receptor
gene in DRG.3 In a previous study by others, preemptive
SAHA was also effective in reducing peripheral nerve
mechanical and thermal hypersensitivity induced by
skin incision along with enhanced spinal cord CXCL1
(KC) and CXCR2 (MIP-2) mRNA expression.57

Relationship of gene expression to the chronicity
of pain
The RT-PCR authenticated the relevance of the three
most overexpressed RAG gene transcripts at both 3
and 28 days post-TIC injury. The RT-PCR indicates
these genes (Sprr1a, Gal, and Atf3) play a role among
perhaps many others in the nerve reparative processes
vital to restoration of nociception and diminished pain
as indicated by others for DRG.41,42,52,58 Although the
Gal and Atf3 were diminished to control levels by 28
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days, the Sprr1a remained elevated at that time point in
both the treated and untreated mice with nerve injury.
Our initial report describing the TIC model demonstrated ATF3 in the TG of mice with TIC nerve injury using
immunocytochemistry.14
The data suggest that the HDACi’s SAHA and MS275 could act as pre-surgical analgesics for the prevention of orofacial neuropathic pain. In another study,
HDACi’s strongly increased GAD65 activity, restored
GABA synaptic function, and relieved sensitized pain
behavior.57 The downregulation of post-synaptic genes,
such as vesicular GABA transporter VGAT and Gad2 in
the GABA inhibitory neurons of the trigeminal spinal
subnucleus caudalis (SpVc) or spinal cord following
nerve injury, leads to neuropathic pain.59,60 Epigenetic
silencing of Kþ channels has previously been demonstrated following spinal nerve ligation.2 In that study,
acetylation was decreased and methylation was
increased in the DRG on histone 3 of the promoter
regions for the K1 channel. These investigators were
able to restore expression of 40 of 42 silenced K1
channel-associated genes following inhibition of G9a,
another methyltransferase that acts on lysine residues
in histone 3.2

Limitations of the study
The aim of this study was to identify evidence of epigenetic changes associated with the TIC nerve injury model
as demonstrated by three independent experimental outputs: (1) altered H3K9 acetylation, (2) altered gene
expression patterns, and (3) effects of chronic histone
deacetylase inhibition. The study is not without limitations. Regarding gene expression profiling, a major limitation is that gene expression profiling has not yet been
done to determine the effect of the HDACi’s on the
transcriptional expression changes associated with the
TIC injury over a rigorous time course. Understanding
the epigenetic mechanisms remains key to a better
understanding of the establishment of chronic pain. In
regard to RAG gene expression, it is not yet known
whether the three differentially expressed RAG genes
selected for RT-PCR authentication (potentially important in nerve repair) are affected by HDACi’s or whether
other genes are the temporally regulated targets of
HDACi’s. Future follow-on studies are needed that
would benefit from the inclusion of both sham and
naı̈ve controls, additional time points, other tissues,
investigation of other epigenetic regulatory pathways,
and the inflammatory response component.
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are playing a role in the transition from acute to persistent pain. Increased expression of nerve RAGs at both
days 3 and 21 provides support for their relevance after
persisting trigeminal nerve injury, as shown with other
peripheral nerve injuries. Several ion channels-associated
genes (Cacna2d1 and Kcnc2) and inflammatory mediator genes (Cd68, Ccl2, Cxcl10, and Cxcl13) had
increased expression after trigeminal nerve injury,
while increases in the inflammatory mediator genes
CD177, Igkv14–126, IgLy6a, Ly6a, and Ighg have not
been reported previously. The present study provides
additional clear immunophenotypic evidence for global
decreased acetylated histone H3K9 in the trigeminal
ganglia, evidence of altered gene expression by microarray, the ability of HDACi’s (MS275, SAHA) to attenuate mechanical hypersensitivity, and the gene expression
increases of nerve RAGs (Sprr1a, Gal, and Atf3) during
the first three weeks after induction of orofacial neuropathic pain using our trigeminal inflammatory constriction nerve injury mouse model. Studying further, the
molecular effects of HDACi’s and their ability to
arrest the transition to chronic hypersensitivity will
lead to valuable insight into understanding the clinical
capabilities of HDACi’s as beneficial therapy for orofacial neuropathic pain.
Author Contributions
RD and LZ performed the behavioral studies as well as processed and analyzed the gene expression profiling. LZ and CD
performed and analyzed the HDAC immunofluorescent localization studies. NL and SEH assisted with the gene expression
profile presentation. CM edited the final manuscript. KW
supervised the studies, their planning, and finalized the manuscript. All authors read, edited, and approved the final manuscript. Danaher and Zhang contributed equally as first authors.
Donley and Laungani contributed equally as second authors.

Authors’ Note
Karin N Westlund is currently affiliated with New Mexico VA
Health Care System.

Acknowledgments
The authors thank Dr. Fei Ma for assistance with the TIC
injury model and Joseph B Cardosi, Nathan Messenger, and
Guan Hanjun for their assistance with counting of H3K9 and
NeuN-positive neurons on TG sections.

Summary

Declaration of Conflicting Interests

Evidence is accumulating that chromatin-modifying
enzymes and associated mechanisms that alter

The author(s) declared no conflicts of interest with respect to
the research, authorship, and/or publication of this article.

18
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this
article: These studies were funded by NIH COBRE grant
2P20RR020145 (to RD, CM, and KNW) and VA Merit
grant BX002695 (to KNW). This communication does not necessarily reflect the views of the Department of Veterans Affairs
or the U.S. government.

References
1. Bai G, Ren K and Dubner R. Epigenetic regulation of
persistent pain. Transl Res 2015; 165: 177–199.
2. Laumet G, Garriga J, Chen SR, Zhang Y, Li DP, Smith
TM, Dong Y, Jelinek J, Cesaroni M, Issa JP and Pan HL.
G9a is essential for epigenetic silencing of K(þ) channel
genes in acute-to-chronic pain transition. Nat Neurosci
2015; 18: 1746–1755.
3. Chiechio S, Zammataro M, Morales ME, Busceti CL,
Drago F, Gereau RW, Copani A and Nicoletti F.
Epigenetic modulation of mGlu2 receptors by histone
deacetylase inhibitors in the treatment of inflammatory
pain. Mol Pharmacol 2009; 75: 1014–1020.
4. Cui SS, Lu R, Zhang H, Wang W and Ke JJ.
Suberoylanilide hydroxamic acid prevents downregulation
of spinal glutamate transporter-1 and attenuates spinal
nerve ligation-induced neuropathic pain behavior.
Neuroreport 2016; 27: 427–434. 7
5. Denk F, Huang W, Sidders B, Bithell A, Crow M, Grist J,
Sharma S, Ziemek D, Rice AS, Buckley NJ and McMahon
SB. HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain. Pain 2013;
154: 1668–1679.
6. Bai G, Wei D, Zou S, Ren K and Dubner R. Inhibition of
class II histone deacetylases in the spinal cord attenuates
inflammatory hyperalgesia. Mol Pain 2010; 6: 51.
7. Vojinovic J and Damjanov N. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med
2011; 17: 397–403.
8. Zhang Z-Y and Schluesener HJ. HDAC inhibitor MS-275
attenuates the inflammatory reaction in rat experimental
autoimmune prostatitis. Prostate 2012; 72: 90–99.
9. Manal M, Chandrasekar MJ, Gomathi P and Nanjan MJ.
Inhibitors of histone deacetylase as antitumor agents: A
critical review. Bioorg Chem 2016; 67: 18–42.
10. Xu K, Dai XL, Huang HC and Jiang ZF. Targeting
HDACs: a promising therapy for Alzheimer’s disease.
Oxid Med Cell Longev 2011; 2011: 143269.
11. Jia H, Wang Y, Morris CD, Jacques V, Gottesfeld JM,
Rusche JR and Thomas EA. The effects of pharmacological inhibition of histone deacetylase 3 (HDAC3) in
Huntington’s disease mice. PLoS One 2016; 11: e0152498.
12. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F,
Khramtsov N, Qian X, Mills E, Berghs SC, Carey N,
Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB,
Lichenstein HS and Sehested M. Determination of the
class and isoform selectivity of small-molecule histone
deacetylase inhibitors. Biochem J 2008; 409: 581–589.

Molecular Pain
13. Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF,
Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I,
Gore SD. A phase 2 study of vorinostat in acute myeloid
leukemia. Haematologica 2009; 94: 1375–1382.
14. Ma F, Zhang L, Lyons D and Westlund KN. Orofacial
neuropathic pain mouse model induced by Trigeminal
Inflammatory Compression (TIC) of the infraorbital
nerve. Mol Brain 2012; 5: 44.
15. Lyons DN, Kniffin TC, Zhang LP, Danaher RJ, Miller
CS, Bocanegra JL, Carlson CR and Westlund KN.
Trigeminal Inflammatory Compression (TIC) injury induces chronic facial pain and susceptibility to anxiety-related
behaviors. Neuroscience 2015; 295: 126–138.
16. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG,
Roayaei J, Stephens R, Baseler MW, Lane HC and
Lempicki RA. The DAVID gene functional classification
tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 2007;
8: R183.
17. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D,
Guo Y, Stephens R, Baseler MW, Lane HC and Lempicki
RA. DAVID bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 2007;
35: W169–W175.
18. Benjamini Y and Hochberg J. Controlling the false discovery rate: a practical and powerful approach to multiple
testing. J Roy Stat Soc B 1995; 57: 289–300.
19. Storey JD and Tibshirani R. Statistical methods for identifying differentially expressed genes in DNA microarrays.
Methods Mol Biol 2003; 224: 149–157.
20. Storey JD and Tibshirani R. Statistical significance for
genomewide studies. Proc Natl Acad Sci U S A 2003;
100: 9440–9445.
21. Ma F, Wang C, Yoder WE, Westlund KN, Carlson CR,
Miller CS and Danaher RJ. Efficacy of herpes simplex
virus vector encoding the human preproenkephalin gene
for treatment of facial pain in mice. J Oral Facial Pain
Headache 2016; 30: 42–50.
22. Danaher RJ, Kaetzel CS, Greenberg RN, Wang C, Bruno
MEC and Miller CS. HIV protease inhibitors alter innate
immune response signaling to double-stranded RNA in
oral epithelial cells: implications for immune reconstitution
inflammatory syndrome? AIDS 2010; 24: 2587–2581.
23. Chaplan SR, Bach FW, Pogrel JW, Chung JM and Yaksh
TL. Quantitative assessment of tactile allodynia in the rat
paw. J Neurosci Methods 1994; 53: 55–63.
24. Martinez-Hernandez A, Bell KP and Norenberg MD.
Glutamine synthetase: glial localization in brain. Science
1977; 195: 1356–1358.
25. Norenberg MD and Martinez-Hernandez A. Fine structural localization of glutamine synthetase in astrocytes of rat
brain. Brain Res 1979; 161: 303–310.
26. Miller KE, Richards BA and Kriebel RM. Glutamine-,
glutamine synthetase-, glutamate dehydrogenase- and
pyruvate carboxylase-immunoreactivities in the dorsal
root ganglion and peripheral nerve. Brain Res 2002;
945: 202–211.

Danaher et al.
27. Weick M, Cherkas PS, Hartig W, Pannicke T, Uckermann
O, Bringmann A, Tal M, Reichenbach A and Hanani M.
P2 receptors in satellite glial cells in trigeminal ganglia of
mice. Neuroscience 2003; 120: 969–977.
28. Hanani M. Satellite glial cells in sensory ganglia: from form
to function. Brain Res Brain Res Rev 2005; 48: 457–476.
29. Dong F, Xie W, Strong JA and Zhang J-M.
Mineralocorticoid receptor blocker eplerenone reduces
pain behaviors in vivo and decreases excitability in smalldiameter sensory neurons from local inflamed dorsal root
ganglia in vitro. Anesthesiology 2012; 117: 1102–1112.
30. Sankaran PK and Sivanandan RJS. Histomorphometric
study of neurons in the trigeminal ganglia in male wistar
albino rats. Recent Res Sci Tech 2012; 4:
28–31. [Mismatch]
31. Wang H, Sun H, Della Penna K, Benz RJ, Xu J, Gerhold
DL, Holder J and Koblan KS. Chronic neuropathic pain is
accompanied by global changes in gene expression and
shares pathobiology with neurodegenerative diseases.
Neuroscience 2002; 114: 529–546.
32. LaCroix-Fralish ML, Austin JS, Zheng FY, Levitin DJ
and Mogil JS. Patterns of pain: meta-analysis of microarray studies of pain. Pain 2011; 152: 1888–1898.
33. Costigan M, Befort K, Karchewski L, Griffin RS, D’Urso
D, Allchorne A, Sitarski J, Mannion JW, Pratt RE and
Woolf CJ. Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the
dorsal root ganglion after peripheral nerve injury. BMC
Neurosci 2002; 3: 16.
34. Maratou K, Wallace VC, Hasnie FS, Okuse K, Hosseini
R, Jina N, Blackbeard J, Pheby T, Orengo C, Dickenson
AH, McMahon SB and Rice AS. Comparison of dorsal
root ganglion gene expression in rat models of traumatic
and HIV-associated neuropathic pain. Eur J Pain 2009;
13: 387–398.
35. LaPaglia DM, Sapio MR, Burbelo PD, Thierry-Mieg J,
Thierry-Mieg D, Raithel SJ, Ramsden CE, Iadarola MJ
and Mannes AJ. RNA-Seq investigations of human postmortem trigeminal ganglia. Cephalalgia 2018; 38: 912–932.
36. Lopes DM, Denk F and McMahon SB. The molecular
fingerprint of dorsal root and trigeminal ganglion neurons.
Front Mol Neurosci 2017; 10: 304.
37. Manteniotis S, Lehmann R, Flegel C, Vogel F, Hofreuter
A, Schreiner BS, Altmüller J, Becker C, Sch€
obel N, Hatt H
and Gisselmann G. Comprehensive RNA-Seq expression
analysis of sensory ganglia with a focus on ion channels
and GPCRs in Trigeminal ganglia. PLoS One 2013;
8: e79523.
38. Ma TC and Willis DE. What makes a RAG regeneration
associated? Front Mol Neurosci 2015; 8: 43.
39. Patodia S and Raivich G. Role of transcription factors in
peripheral nerve regeneration. Front Mol Neurosci 2012;
5: 8.
40. Lynds R, Lyu C, Lyu GW, Shi XQ, Rosén A, Mustafa K
and Shi TJS. Neuronal plasticity of trigeminal ganglia in
mice following nerve injury. J Pain Res 2017; 10: 349–357.
41. Gey M, Wanner R, Schilling C, Pedro MT, Sinske D and
Kn€
oll B. Atf3 mutant mice show reduced axon regeneration and impaired regeneration-associated gene induction

19

42.

43.

44.

45.

46.

47.

48.

49.

50.

51.

52.

53.

54.

55.

after peripheral nerve injury. Open Biol 2016; 6:
pii: 160091.
Reinhold AK, Batti L, Bilbao D, Buness A, Rittner HL
and Heppenstall PA. Differential transcriptional profiling
of damaged and intact adjacent dorsal root ganglia neurons in neuropathic pain. PLoS One 2015; 10: e0123342.
Bonilla IE, Tanabe K and Strittmatter SM. Small prolinerich repeat protein 1A is expressed by axotomized neurons
and promotes axonal outgrowth. J Neurosci 2002;
22: 1303–1315.
Starkey ML, Davies M, Yip PK, Carter LM, Wong DJ,
McMahon SB and Bradbury EJ. Expression of the
regeneration-associated protein SPRR1A in primary sensory neurons and spinal cord of the adult mouse following
peripheral and central injury. J Comp Neurol 2009;
513: 51–68.
Lang R, Gundlach AL and Kofler B. The galanin peptide
family: receptor pharmacology, pleiotropic biological
actions, and implications in health and disease.
Pharmacol Ther 2007; 115: 177–207.
Xu XF, Zhang DD, Liao JC, Xiao L, Wang Q and Qiu W.
Galanin and its receptor system promote the repair of
injured sciatic nerves in diabetic rats. Neural Regen Res
2016; 11: 1517–1526.
Lang R, Gundlach AL, Holmes FE, Hobson SA, Wynick
D, Hokfelt T and Kofler B. Physiology, signaling, and
pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev 2015;
67: 118–175.
Dooley R, Harvey BJ and Thomas W. Non-genomic
actions of aldosterone: From receptors and signals to
membrane targets. Mol Cell Endocrinol 2012;
350: 223–234.
Harkany T, Mackie K and Doherty P. Wiring and firing
neuronal networks: endocannabinoids take center stage.
Curr Opin Neurobiol 2008; 18: 338–345.
Finelli MJ, Wong JK and Zou H. Epigenetic regulation
of sensory axon regeneration after spinal cord injury.
J Neurosci 2013; 33: 19664–19676.
Toth C, Brussee V, Martinez JA, McDonald D,
Cunningham FA and Zochodne DW. Rescue and regeneration of injured peripheral nerve axons by intrathecal insulin. Neuroscience 2006; 139: 429–449.
Jing X, Wang T, Huang S, Glorioso JC and Albers KM.
The transcription factor Sox11 promotes nerve regeneration through activation of the regeneration-associated gene
Sprr1a. Exp Neurol 2012; 233: 221–232. Jan
Scarlata S, Garwain O, Williams L, Burguera IG, Rosati
B, Sahu S, Guo Y, Philip F, Golebiewska U.
Phosphoinositide-specific-phospholipase Cb (PLCb) is the
main effector of Gaq stimulation which is coupled to
receptors. Adv Biol Regul 2016; 61: 51–57.
Khangura RK, Bali A, Jaggi AS and Singh N. Histone
acetylation and histone deacetylation in neuropathic
pain: An unresolved puzzle? Eur J Pharmacol 2017;
795: 36–42.
Uchida H, Ma L and Ueda H. Epigenetic gene silencing
underlies C-fiber dysfunctions in neuropathic pain. J
Neurosci 2010; 30: 4: 4806–4814.

20
56. Uchida H, Matsushita Y, Araki K, Mukae T and Ueda H.
Histone deacetylase inhibitors relieve morphine resistance
in neuropathic pain after peripheral nerve injury. J Pharm
Sci 2015; 128: 208–211.
57. Sun Y, Sahbaie P, Liang D-Y, Li W-W, Li X-Q, Shi X-Y
and Clark JD. Epigenetic regulation of spinal CXCR2 signaling in incisional hypersensitivity in mice. Anesthesiology
2013; 119: 1198–1208.
58. Hill CE, Harrison BJ, Rau KK, Hougland MT, Bunge
MB, Mendell LM and Petruska JC. Skin incision induces

Molecular Pain
expression of axonal regeneration-related genes in adult rat
spinal sensory neurons. J Pain 2010; 11: 1066–1073.
59. Zhang Z, Cai YQ, Zou F, Bie B and Pan ZZ. Epigenetic
suppression of GAD65 expression mediates persistent
pain. Nat Med 2011; 17: 1448–1455.
60. Okada-Ogawa A, Nakaya Y, Imamura Y, Kobayashi M,
Shinoda M, Kita K, Sessle BJ and Iwata K. Involvement
of medullary GABAergic system in extraterritorial neuropathic pain mechanisms associated with inferior alveolar
nerve transection. Exp Neurol 2015; 267: 42–52.

